[Featured Stock] CJ Bioscience Rises on Expectations for AI New Drug Platform Technology Transfer

CJ Bioscience is showing strong performance in the early trading session. The stock price is believed to be driven by expectations of overseas technology licensing of the company's AI (artificial intelligence)-based new drug platform.

As of 9:24 a.m. on the 25th, CJ Bioscience is trading at 11,190 KRW, up 12.46% (1,240 KRW) from the previous close. During the session, the price surged to as high as 12,930 KRW, reaching the upper limit.

The reason behind the stock price increase is interpreted as expectations for technology licensing of CJ Bioscience's AI-based new drug platform 'EasyGM.' The company recently stated at the 'European Crohn's and Colitis Organisation (ECCO)' held in Berlin, Germany, that "we recognized a high demand for new drug development using the platform from big pharma," and added, "technology licensing of the platform could proceed in the form of partnerships or various methods such as transfer of usage rights."

EasyGM is used to discover new drug candidates and biomarkers based on microbiome big data. At this conference, CJ Bioscience also presented research results of the inflammatory bowel disease (IBD) new drug pipeline 'CJRB-201' discovered through EasyGM. The company has set a goal to license out three new drug candidate pipelines by next year.